Pharma Wells Fargo Managing Director Mohit Bansal joins Yahoo Finance Live anchors Rachelle Akuffo and Anjalee Khemlani to discuss pharmaceutical earnings amid COVID uncertainty, the impact of diabetic weight loss drugs on the market, and the outlook for drugmakers.

Pharma earnings: COVID ‘is highly uncertain for this year,' analyst says

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Bristol Myers (BMY) Q4 Earnings: A Look at Key Metrics

Economic Data Deluge

Bristol-Myers Squibb Company (NYSE:BMY ) Q4 2022 Earnings Conference Call February 2, 2023 9:00 AM ET Company Participants Timothy Power - VP & Head, IR Giovanni Caforio - Chairman & CEO David Elkins - EVP & CFO Christopher Boerner - EVP & Chief Commercialization Officer Samit Hirawat - EVP & Chief Medical Officer, Global Drug Development Conference Call Participants Geoffrey Meacham - Bank of America Chris Shibutani - Goldman Sachs Christopher Schott - JPMorgan Seamus Fernandez - Guggenheim Securities Stephen Scala - Cowen and Company Timothy Anderson - Wolfe Research Evan Seigerman - BMO Capital Markets Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo Carter Gould - Barclays Matthew Phipps - William Blair Robyn Karnauskas - Truist Securities Olivia Brayer - Cantor Fitzgerald Andrew Baum - Citigroup Colin Bristow - UBS Operator Good morning. My name is Dennis, and I will be your conference operator today.

Bristol-Myers Squibb Company (BMY) Q4 2022 Earnings Call Transcript

Bristol Myers (BMY) delivered earnings and revenue surprises of 6.43% and 2.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Q4 Earnings and Revenues Surpass Estimates

Bristol Myers posts fourth-quarter earnings of $1.82 a share on revenue of $11.4 billion.

Bristol Myers Stock Rises as Revenue Falls on Lower Revlimid Sales but Profit Tops Estimates

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.